

Flucytosine (Ancobon®)

Spectrum of Activity:

- Flucytosine has activity against *Candida* spp., including *C. glabrata* and *C. krusei*, and *Cryptococcus neoformans*.
- Flucytosine does not have clinically useful activity against mold and dimorphic fungi are resistant to this agent.

Acceptable uses

- Treatment
 - Cryptococcal meningitis in combination with amphotericin B
 - Cryptococcal and *Candida* endocarditis, pneumonia, septicemia and urinary tract infections in combination with amphotericin B

Unacceptable uses

- Monotherapy
 - Exception with azole-resistant candiduria
- Treatment of infections due to molds or dimorphic fungi

Dosing

- Treatment
 - 100 mg/kg/day in 4 divided doses
- Dose Adjustments:
 - Recommended for renal impairment
 - Recommended for flucytosine peak concentrations of > 100 mg/L or clinically significant leukopenia due to flucytosine
 - No dosing adjustments recommended for hepatic impairment

Monitoring

- Adverse Reactions: bone marrow suppression, GI intolerance, headache, pruritis, hepatotoxicity
- Labs/Tests: CBC, AST/ALT at baseline and every 1-2 weeks after, renal function

Notes

- Dosing should be based on ideal body weight in obese patients